Figure 1.
Figure 1. Duration of CR. CR duration is shown for patients at 50 μg/kg by consolidation cycles received (A) and by those evaluable for MRD (B). Durations of MRD-negative CR (C) and MRD negativity in blood for patients achieving CR or partial response are shown (D). MRD evaluation at the National Cancer Institute used multicolor flow cytometry (detection level of 0.002% to 0.006%) in blood and BMA (see supplemental Table 1 for details). MRD was also determined by immunohistochemistry of the bone marrow biopsy. Bone marrows were typically performed after cytopenias resolved consistent with CR, at end of treatment, annually at 0.5 to 2.5 years after best response, and every 2 years thereafter. Flow cytometry of blood was performed precycle, at end of treatment, every 6 months after best response until 2.5 years, and annually thereafter. Time to achieve and duration of response were calculated using Kaplan-Meier, with curves compared by log-rank. PR, partial response.

Duration of CR. CR duration is shown for patients at 50 μg/kg by consolidation cycles received (A) and by those evaluable for MRD (B). Durations of MRD-negative CR (C) and MRD negativity in blood for patients achieving CR or partial response are shown (D). MRD evaluation at the National Cancer Institute used multicolor flow cytometry (detection level of 0.002% to 0.006%) in blood and BMA (see supplemental Table 1 for details). MRD was also determined by immunohistochemistry of the bone marrow biopsy. Bone marrows were typically performed after cytopenias resolved consistent with CR, at end of treatment, annually at 0.5 to 2.5 years after best response, and every 2 years thereafter. Flow cytometry of blood was performed precycle, at end of treatment, every 6 months after best response until 2.5 years, and annually thereafter. Time to achieve and duration of response were calculated using Kaplan-Meier, with curves compared by log-rank. PR, partial response.

Close Modal

or Create an Account

Close Modal
Close Modal